Literature DB >> 16777585

Major histocompatibility genes and ankylosing spondylitis.

John D Reveille1.   

Abstract

The association of HLA-B27 with ankylosing spondylitis accounts for nearly 40% of the total disease risk. However, fewer than 5% of B27-positive individuals in the general population become affected. Genomewide scans suggest that other major histocompatibility complex genes further heighten this risk, although linkage disequilibrium with HLA-B27 has confounded their precise identification. Over 31 variants of HLA-B27 have been identified to date, which have evolved from the original B27 allele (B*2705) along three geographic lines. HLA-B*2705 and B*2702 are the primary subtypes in Caucasians with spondylitis, and B*2704 and B*2707 are the primary subtypes in Asians. HLA-B*2706 and B*2709 are not disease associated. There are four theories of how HLA-27 causes spondyloarthritis: (1) HLA-B27 presents a bacterially derived 'arthritogenic peptide' (not yet identified); (2) misfolding or homodimerization of HLA-B27 heavy chains results in a pro-inflammatory response; (3) HLA-B27-positive individuals have deficient intracellular killing of arthritogenic organisms; and (4) HLA-B27 itself, due to sequence homology with bacterial proteins, becomes autoantigenic.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16777585     DOI: 10.1016/j.berh.2006.03.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  30 in total

1.  Screening and evaluating the mimic peptides as a useful serum biomarker of ankylosing spondylitis using a phage display technique.

Authors:  Min Wang; Xianping Li; Jingwei Chen; Yong Zhou; Hong Cao; Xiang Wu; Hongmin Jiang
Journal:  Rheumatol Int       Date:  2010-03-19       Impact factor: 2.631

Review 2.  The quest for better understanding of HLA-disease association: scenes from a road less travelled by.

Authors:  Joseph Holoshitz
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

Review 3.  An update on the genetics of HLA B27-associated acute anterior uveitis.

Authors:  Tammy M Martin; James T Rosenbaum
Journal:  Ocul Immunol Inflamm       Date:  2011-04       Impact factor: 3.070

Review 4.  Human Leukocyte Antigen-Disease Associations in Rheumatoid Arthritis.

Authors:  Vincent van Drongelen; Joseph Holoshitz
Journal:  Rheum Dis Clin North Am       Date:  2017-08       Impact factor: 2.670

Review 5.  Genetics of ankylosing spondylitis: an update.

Authors:  Proton Rahman
Journal:  Curr Rheumatol Rep       Date:  2007-10       Impact factor: 4.592

6.  HLA-B27 subtypes in Turkish patients with ankylosing spondylitis and healthy controls.

Authors:  Muradiye Acar; Tulin Cora; Recep Tunc; Hasan Acar
Journal:  Rheumatol Int       Date:  2011-09-17       Impact factor: 2.631

7.  Optimization of an in-house PCR method for the detection of HLA-B*27 alleles.

Authors:  Noor Afshan; Mukarram Bashir; Hamid Nawaz Tipu; Mohammad Hussain
Journal:  Biomed Rep       Date:  2018-02-01

8.  High frequencies of HLA-B27 in Chinese patients with suspected of ankylosing spondylitis.

Authors:  Xiang Liu; Yi-Rong Li; Li-Hua Hu; Zhi-Ming Zhou; Feng-Hua Chen; Yong Ning; Qun-Feng Yao
Journal:  Rheumatol Int       Date:  2009-09-23       Impact factor: 2.631

9.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

10.  Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosis.

Authors:  David R Karp; Nishanth Marthandan; Steven G E Marsh; Chul Ahn; Frank C Arnett; David S Deluca; Alexander D Diehl; Raymond Dunivin; Karen Eilbeck; Michael Feolo; Paula A Guidry; Wolfgang Helmberg; Suzanna Lewis; Maureen D Mayes; Chris Mungall; Darren A Natale; Bjoern Peters; Effie Petersdorf; John D Reveille; Barry Smith; Glenys Thomson; Matthew J Waller; Richard H Scheuermann
Journal:  Hum Mol Genet       Date:  2009-11-18       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.